Coloplast A/S

Latest Results (11.09.2025):

Coloplast A/S reported its Q3 2024/25 financial results, achieving an organic growth of 7% and an EBIT margin of 28%. The company’s reported revenue in DKK increased by 1%, despite negative impacts from currency fluctuations and the divestment of the Skin Care division.

Organic Growth Across Business Areas

Coloplast saw robust organic growth in all major business segments: Ostomy Care grew by 6%, Continence Care by 8%, Voice and Respiratory Care by 9%, Advanced Wound Care by 4%, and Interventional Urology by 4%. This broad-based expansion highlights the company's strong market presence and effective product offerings.

Impact of Divestments and Currency Effects

The reported revenue growth was tempered by a 1% negative impact from currency fluctuations and the divestment of the Skin Care division. Specifically, the Advanced Wound Care segment faced a decline in China due to a product return, expected to negatively impact revenues by approximately DKK 80 million in H2.

EBIT and Profitability

EBIT for Q3 2024/25 stood at DKK 1,915 million, marking a 2% increase from the previous year and maintaining the EBIT margin at 28%. This demonstrates Coloplast’s continued focus on profitability despite external challenges.

Strategic Leadership Changes

To support the new company strategy towards 2030, Coloplast announced changes to its Executive Leadership Team. These adjustments are aimed at enhancing strategic execution and driving future growth.

Future Guidance

Coloplast maintains its financial guidance for FY 2024/25, expecting an organic growth of around 7% and an EBIT margin before special items between 27-28%. The company anticipates that growth momentum will improve in Q4, following a strong start in July.